Vagifem is superior to vaginal Premarin in induction of endometrial thickness in the frozen-thawed cycle patients with refractory endometria: A randomized clinical trial

Jaleh Zolghadri¹, ² M.D., Hossein Haghbin¹ M.D., Nasrin Dadras¹ M.D., Shabnam Behdin¹ D.M.D.

Abstract

Background: Embryo transfer to a developed endometrium is an important prognostic factor in frozen-thawed embryo transfer cycle outcome. Vaginal estrogen, such as Vagifem vaginal tablets and Premarin vaginal cream, is a regimen used for the patients with refractive endometria.

Objective: Our objective was to compare the effects of Vagifem and Premarin on the endometrial thickness of the patients with refractive endometria.

Materials and Methods: In this randomized clinical trial, 30 patients with refractive endometria in frozen-thawed embryo transfer cycles received Vagifem vaginal tablets and 30 women received Premarin vaginal cream. Endometrial thickness was measured on the 14th day of drug administration.

Results: Comparing the endometrial thicknesses of the two groups showed that the endometria of the Vagifem group was significantly thicker than that of the Premarin group (5.93±0.38 vs. 6.74±0.32; p<0.001).

Conclusion: Vagifem is superior to Premarin in induction of endometrial thickness in frozen-thawed embryo transfer cycles in the patients with refractive endometria.

Key words: Premarin, Estradiol, Endometrium, Infertility, Human.

Registration ID in IRCT: IRCT2012103911306N1

This article extracted from M.D. thesis. (Hossein Haghbin)

Introduction

Success of embryo transfer, one of the most important steps of assisted reproductive technology (ART), depends on good quality embryo, receptive endometrium, and an appropriate interaction amongst them (1, 2). Endometrium must be mature to become receptive to the functional embryo. Follicular and luteal phases are stages of a natural ovulatory cycle that, by controlling the right amount of body estrogen (E₂) and progesterone (P), lead to proliferation of the endometrial cells and induction of endometrial receptivity (3).

In 1983, a great achievement was gained in the field of ART when the endometrium of a woman with ovarian failure was made receptive by the means of exogenous E₂ and P administration (4). Since then, there have been many developments in this field. Studies have shown that E₂ and P are sufficient for making an endometrium receptive in the women with no function of ovaries (5). Yet, routes, dosages, and duration of administration of these drugs are the variables that have been subject to many revisions and improvements and no evidence is available regarding the superiority of one method to another (6). In general, E₂ can be administered through oral, intra-muscular, vaginal, and transdermal routes. Oral route is simple, easy, and effective. Transdermal route, which is used when the oral route is not effective, leads to more Endometrial Thickness (ET) but with the same pregnancy rates compared to the oral route (6, 7).

Endometrium development is controlled by serial ultrasonography in artificial cycles (8). A positive correlation has been found between ET and pregnancy rate in In Vitro Fertilization (IVF) and embryo transfer patients. Moreover, other studies have reported adverse effects of excessively increased ET on decreasing the pregnancy rate (9-13). In contrast, some studies failed to find a relationship between...
ET and pregnancy rate (14-17). Furthermore, Remohi et al revealed an association between ET and implantation rate, underscoring the significance of ET in embryo transfer cycles (18). Nevertheless, not all the patients’ endometria respond to programmed sequential treatment with exogenous E2 and P.

Up to now, many techniques, including aspirin, sildenafil, pentoxifylline-vitamin E, repeated endometrial biopsies, and prolonging the duration of E2 therapy, have been developed to improve ET in cases with poorly responsive endometria (19-23). Nonetheless, many of these therapies are far from perfect, and controversies exist regarding their effectiveness. Vaginal E2 is yet another method for endometrial receptivity improvement (23). Not only does this route result in high E2 serum levels, but it also causes a higher level in the endometrium; hence, it is used in refractory cases (24).

Premarin and Vagifem are examples of vaginal E2 regimens. Premarin or conjugated equine estrogen (CEE) is a naturally occurring E2 derived from urine of mares. Conjugation enables the compound to be water-soluble and more absorbable (25). Premarin is also the third most common drug used in the U.S. (26). Vagifem is a vaginally delivered Ethinyl Estradiol tablet. Estradiols are the most commonly used synthetic estrogens (25). Besides, Vagifem has the advantage of being superior to other vaginal estrogens in the Hormone Replacement Therapy (HRT) patients' point of view (27, 28). Considering the controversy regarding the use of a therapy for the embryo transfer patients with refractory endometria to the initial therapies, we decided to study the effects of these two therapies, namely Vagifem and vaginal Premarin, on ET development.

Materials and methods

The present randomized clinical trial (RCT) was conducted on the women with failure to achieve optimal ET (<3 mm) in frozen-thawed embryo transfer cycles by conventional estrogen therapy. In IVF cycles, some embryos are cryopreserved for later use in the subsequent frozen-thawed embryo transfer cycles. Even increasing the estrogen dosage or changing the type of estrogen to Ethinyl Estradiol was not effective in these women (29). Written informed consents were obtained from all the study patients before recruitment and the study was approved by the Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran. Consort flow diagram of the study is demonstrated in figure 1.

Using computer generated block randomization method, 61 women in the reproductive age were sampled from the infertile patients aging 24-42 years who were unresponsive to conventional and added E2 regimens of embryo transfer cycles in Ghadir Hospital, Shiraz, Iran, a tertiary referral center, in 2013. Sample size was estimated by calculation of variance of ET of similar patients in our previous pilot studies. The exclusion criteria of the study were having a previous medical history of tuberculosis, Asherman syndrome, endometriosis, uterine leiomyoma, pelvic inflammatory diseases, collagen vascular diseases, and other diseases that secondarily hinder pregnancy. Smokers and alcohol abusers were also excluded from this study. Patients with undiagnosed Abnormal Uterine Bleeding (AUB), history of thromboembolic diseases, E2 dependent malignant neoplasms, and liver disease were also excluded from this study due to contraindications to E2 (30). All the patients underwent pelvic ultrasonography one month prior to the study to rule out any polyps or anatomical problems.

The patients were randomly divided into two groups. The patients in group 1 (n=30) received 1.25 mg/day (half of vaginal applicator) Premarin in the form of vaginal cream (Estromarin vaginal cream, 2.5 mg, Aburaihan pharmaceutical, Iran). On the other hand, those in group 2 (n=31) received 20 micrograms Vagifem (1 tablet Bid) (vaginal tablet, 10 mcg, Novo Nordisk, Denmark). One of the volunteers in group 2 exited the study in follow-up. It should be mentioned that both regimens were added to the conventional E2 regimen. Due to the fact that Vagifem was administered in the form of vaginal tablets and Premarin in the form of vaginal cream, blinding was impossible on the side of the patients.

From the second day of the menstrual cycle, the patients received 8 mg or 4 oral tablets of Estradiol Valerate (Progynova, 2mg tablets, Schering, Germany) daily. Vagifem and Premarin were added from the third day of the menstrual cycle for 14 days.
Ultrasonographic measurement of ET was performed in both groups. The ET was measured in this period and at the end of the 14th day of Vagifem or Premarin administration, which equals to the 16th day of the menstrual cycle, and was compared between the two groups.

From the 16th day of the menstrual cycle, 400mg per day of vaginal P suppositories (Cyclogest vaginal suppository 200 mg: Shire, Andover, Hants, UK) was administered. Finally, on the 19th day of the menstrual cycle, frozen-thawed embryos were transferred to our patients by an expert obstetrician. After confirmation of an adequately full bladder, the uterine cavity was found through ultrasound. Then, the embryos were transferred in the lithotomy position and were deposited at 1.5 cm below the uterine fundus. The catheter was withdrawn gently, while maintaining the pressure on the syringe plunger.

**Statistical analysis**

In this study, ET was compared between the two groups using Student \( t \)-test. Besides, p-values less than 0.05 were considered as statistically significant.

**Results**

In this RCT, 2 groups of Premarin and Vagifem were compared in terms of ET. Within-group comparisons were also made in the subjects of each group before and after the therapy. Table I shows some possible confounding factors, including age, Body Mass Index (BMI), and the duration of infertility in the Premarin and Vagifem groups. As the table depicts, no significant difference was found between the two groups regarding these factors. As figure 2 shows, the initial ET was also the same between the two groups. According to figure 2, ET in the Premarin group ranged from 5.1-6.7 mm, with a mean±SD of 5.93±0.38 millimeters. On the other hand, this measure ranged from 6-7.5 mm, with a mean±SD of 6.74±0.32 mm in the Vagifem group.

According to the results of student \( t \)-test, both measures significantly out-weigh their initial values which were less than 3 millimeters (p<0.001). Furthermore, comparison of the two groups' ETs showed that the ET of the Vagifem group was significantly higher compared to that of the Premarin group (5.93±0.38 vs. 6.74±0.32; p<0.001). In addition, the mean difference (±c) was 0.81±0.09.

| Table I: Age, BMI, and duration of infertility in Premarin and Vagifem groups |
|----------------|----------------|--------|
|                | Premarin group | Vagifem group | p-value |
| Age (years)    | 31.93 ± 4.30   | 33.06 ± 3.08 | 0.248   |
| BMI (kg/m²)    | 23.26 ± 1.24   | 23.76 ± 1.47 | 0.171   |
| Duration of infertility (years)| 6.76 ± 1.59 | 6.26 ± 1.38 | 0.200   |

Number are presented as mean±SD. Student t-test was used for comparison. * Not significant.
Figure 1. Endometrial thicknesses (millimeters) before and after the therapy with Premarin and Vagifem. *p<0.001. Error bars: +/- 2 SD bars: +/- 2 SD

Discussion

Although some studies have failed to find a relationship between ET and pregnancy rate, most experts agree that embryo transfer to endometria with >7mm thickness is a good prognostic indicator of pregnancy after embryo transfer (9-17). Up to now, different E2 and P regimen protocols with various routes of administration have been introduced (6). Other formulations, such as aspirin, and methods, such as repeated endometrial biopsies, have also been suggested. However, none of these has been proven to be superior to others (6, 19, 22).

Considering the fact that Vagifem and Premarin are widely used medications and controversial evidence exists regarding the superiority of a regimen over the other for the patients with refractory endometria, we decided to compare these two medications. Up to now, no studies have compared the role of Vagifem and Premarin in ET development in IVF and embryo transfer patients. The findings of the present study revealed the superiority of Vagifem to Premarin in ET improvement. Vagifem is also more acceptable in the HRT patients’ point of view (27).

In this study, we focused on ET, while there are more variables playing part in successfulness of frozen-thawed embryo transfer cycles. In a comprehensive retrospective study on 2450 patients, Cai et al concluded that out of the 27 candidate variables for prognosis of a good IVF and embryo transfer cycle outcome, 9 had the highest correlation with success in IVF and embryo transfer cycles (32). These variables included age, quality and quantity of embryos, ET, and duration of infertility. Out of these factors, the total number of good-quality embryos had the highest correlation with successful outcomes, even higher than ET. This can explain the reason for lower success rate when the number of the good-quality embryos dropped significantly in the women older than 35 years (32).

Success also depends on other factors, such as endometrial texture and sub-endometrial blood flow. In a study on 1933 women, Zhao et al came to this conclusion that in an endometrium with an adequate thickness of 7-14 mm, a triple-line pattern conferred the best clinical outcome (33). Singh et al also ruled in sub-endometrial blood flow as another prognostic factor (34). Although ultra-low-dose vaginal E2 is considered not effective on endometrium and, therefore, safe for HRT in postmenopausal women, proper vaginal E2 doses are more effective than oral E2 and recommended for use in embryo transfer patients over oral E2 (24).
The patients who have had a refractory endometrium to conventional oral E2 are even more suitable for vaginal route (35). Serum and Endometrial E2 concentration is significantly higher in vaginal route compared to oral route (35, 36). Fanchin et al compared oral and vaginal route by monitoring ET and uterine perfusion after 14 days of E2 administration in 39 infertile women. Their study proved that vaginal route leads to a superior ET and uterine perfusion compared to oral route (37). The aforementioned studies depict that vaginal E2s are the best candidates for patients with refractive endometria. While Premarin and Vagifem are the most commonly used and studied vaginal estrogens for HRT, their use for embryo transfer patients is significantly less studied. This study has researched this important and novel area.

In spite of the fact that this study showed Vagifem to be superior to vaginal Premarin cream and previous studies have also revealed the superiority of Vagifem to Premarin from the HRT patients’ point of view. More studies with larger sample sizes are required to be conducted on these and further issues. For example, the pregnancy outcomes are needed to be compared in order to fully support Vagifem over Premarin.

Acknowledgments

The authors would like to thank the Infertility Research Center of Ghadir Hospital, Shiraz, Iran for their cooperation in the study and their financial support. They are grateful for Ms. A. Keivanshekouh at the Research Improvement Center of Shiraz University of Medical Sciences for improving the use of English in the manuscript. Thanks also go to Mr. Sayadi for his assistance in statistical analysis of the data.

Conflict of interest

The authors declare that there is no conflict of interest in this study.

References

1. Díaz-Gimeno P, Horcajadas JA, Martínez-Conejero JA, Esteban FJ, Alama P, Pellicer A, et al. A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature. *Fertil Steril* 2011; 95: 50-60.
2. Achache H, Revel A. Endometrial receptivity markers, the journey to successful embryo implantation. *Hum Reprod Update* 2006; 12: 731-746.
3. Wang H, Dey SK. Roadmap to embryo implantation: clues from mouse models. *Nat Rev Genet* 2006; 7: 185-199.
4. Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P. The establishment and maintenance of pregnancy using in vitro fertilization and embryo donation in a patient with primary ovarian failure. *Nature* 1984; 307: 174-175.
5. Paulson RJ, Hatch IE, Lobo RA, Sauer MV. Cumulative conception and live birth rates after oocyte donation: implications regarding endometrial receptivity. *Hum Reprod* 1997; 12: 835-839.
6. Glujovsky D, Pesce R, Fiszbajn G, Sueldo C, Hart RJ, Clapponi A. Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes. *Cochrane Database Syst Rev* 2010; (1): CD006359.
7. Krasnow JS, Lessey BA, Naus G, Hall LL, Guizick DS, Berga SL. Comparison of transdermal versus oral estradiol on endometrial receptivity. *Fertil Steril* 1996; 65: 332-336.
8. Hofmann GE, Thie J, Scott RT Jr, Navot D. Endometrial thickness is predictive of histologic endometrial maturation in women undergoing hormone replacement for ovum donation. *Fertil Steril* 1996; 66: 380-383.
9. Dessolle L, Darai E, Cornet D, Rouzier R, Coutant C, Mandelbaum J, AntoineJM: Determinants of pregnancy rate in the donor oocyte model: amultivariate analysis of 450 frozen-thawed embryo transfers. *Hum Reprod* 2009; 24: 3082-3089.
10. Gonen Y, Casper RF. Prediction of implantation by the sonographic appearance of the endometrium during controlled ovarian stimulation for in vitro fertilization (IVF). *J In Vitro Fert Embryo Transf* 1990; 7: 146-152.
11. Zenke U, Chetkowsky RJ. Transfer and uterine factors are the majorrecipient-related determinants of success with donor eggs. *Fertil Steril* 2004, 82: 850-856.
12. Rashidi BH, Sadeghi M, Jafarabadi M, Tehraninejad ES. Relationships between pregnancy rates following in vitro fertilization ointracytoplasmic sperm injection and endometrial thickness and pattern. *Eur J Obstet Gynecol Reprod Biol* 2005; 120: 179-184.
13. Schild RL, Knobloch C, Dorn C, Fimmers R, Van der Ven H, Hansmann M. Endometrial receptivity in an in vitro fertilization program as assessed by spiral artery blood flow, endometrial thickness, endometrial volume, and uterine artery blood flow. *Fertil Steril* 2001; 75: 361-366.
14. Sharma R, Rao K, Srivinas MS, Jones T. Is endometrial thickness on the day of ET really predictive on the IVF outcome? IJIFM 2012; 3: 40-47.
15. Laasch C, Puscheck E. Cumulative embryo score, not endometrial thickness, is best for pregnancy prediction in IVF. *J Assist Reprod Genet* 2004; 21: 47-50.
16. Garcia-Velasco JA, Isaza V, Caligara C, Pellicer A, Remohi J, Simon C. Factors that determine
discordant outcome from shared oocytes. Fertil Steril 2003; 80: 54-60.
17. Dietterich C, Check JH, Choe JK, Nazari A, Lurie D. Increased endometrial thickness on the day of human chorionic gonadotropin injection does not adversely affect pregnancy or implantation rates following in vitro fertilization-embryo transfer. Fertil Steril 2002; 77: 781-786.
18. Remohi J, Ardiles G, Garcia-Velasco JA, Gaitan P, Simon G, Pellicer A. Endometrial thickness and serum estradiol concentrations as predictors of outcome in oocyte donation. Hum Reprod 1997; 12: 2271-2276.
19. Wada I, Hsu CC, Williams G, Macnamee MC, Brinsden PR. The benefits of low-dose aspirin therapy in women with impaired uterine perfusion during assisted conception. Hum Reprod 1994; 9: 1954-1957.
20. Sher G, Fisch JD. Vaginal sildenafil (Viagra): a preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF. Hum Reprod 2000; 15: 806-809.
21. Letur-Konirsch H, Guis F, Delanian S. Uterine restoration by radiation sequelae regression with combined pentoxifylline-tocopherol: a phase II study. Fertil Steril 2002; 77: 1219-1226.
22. Barash A, Dekel N, Fieldust S, Segal I, Schechtman E, Granot I. Local injury to the endometrium doubles the incidence of successful pregnancies in patients undergoing in vitro fertilization. Fertil Steril 2003; 79: 1317-1322.
23. Tourgeman DE, Slater CC, Stanczyk FZ, Paulson RJ. Endocrine and clinical effects of micronized estradiol administered vaginally or orally. Fertil Steril 2001; 75: 200-202.
24. Tourgeman DE, Gentzchein E, Stanczyk FZ, Paulson RJ. Serum and tissue hormone levels of vaginally and orally administered estradiol. Am J Obstet Gynecol 1999; 180: 1480-1483.
25. Ruggiero RJ, Likis FE. Estrogen: physiology, pharmacology, and formulations for replacement therapy. J Midwif Women’s Health 2002; 47: 130-138.
26. Scott-Levin. The top 200 prescriptions for 2000 by number of US prescriptions dispensed. Newton (PA): Scott-Levin; 2002. http://www.rxlist.com/top200.htm.
27. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17β estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000; 7: 156-161.
28. Cholet JA. Efficacy and safety of ultra-low-dose Vagifem (10 mcg). Patient Prefer Adherence 2011; 5: 571-574.
29. Mains L, Van Voorhis BJ. Optimizing the technique of embryo transfer. Fertil Steril 2010; 94: 785-790.
30. Gergeley, Robert Z. “Sonography guided embrytransfer for in vitro fertilization.” U.S. Patent No. 7,322,931. 29 Jan. 2008.
31. Notelovitz M. Estrogen replacement therapy: indications, contraindications, and agent selection. Am J Obstet Gynecol 1989; 161: 1832-1841.
32. Cai QF, Wan F, Huang R, Zhang HW. Factors predicting the cumulative outcome of IVF/ICSI treatment: a multivariable analysis of 2450 patients Hum Reprod 2011; 26: 2532-2540.
33. Zhao J, Zhang Q, Li Y. The effect of endometrial thickness and pattern measured by ultrasonography on pregnancy outcomes during IVF-ET cycles. Reprod Biol Endocrinol 2012; 10: 100.
34. Singh N, Bahadur A, Mittal S, Malhotra N, Bhatt A. Predictive value of endometrial thickness, pattern and sub-endometrial blood flows on the day of hCG by 2D doppler in in-vitro fertilization cycles: A prospective clinical study from a tertiary care unit. J Hum Reprod Sci 2011; 4: 29-33.
35. Tourgeman DE, Slater CC, Stanczyk FZ, Paulson RJ. Endocrine and clinical effect of micronized estradiol administered vaginally or orally. Fertil Steril 2001; 75: 200-202.
36. Tourgeman DE, Boostanfar R, Chang L, Lu J, Stanczyk FZ, Paulson RJ. Is there evidence for preferential delivery of ovarian estradiol to the endometrium? Fertil Steril 2001; 75: 1156-1158.
37. Fanchin R, Righini C, Schönauer LM, Olivennes F, Cunha Filho JS, Frydman R. Vaginal versus oral E2 administration: effects on endometrial thickness, uterine perfusion, and contractility. Fertil Steril 2001; 76: 994-995.